A few thoughts, don't really know if the RS will be 3 to 1 or 10 to 1 or somewhere in between.
Per the filing Amgen with 24 million and JPM with 15+m will surly weigh in.
Will the company keep the authorize share count the same amount or reduced that also. I believe it's at 250m. (need to validate)
How does the company options plan and share grants get threated? Need to investigate this element.
Reviewing the OrbiMed share rights as well as the recent awards to Ian and Michael.
Now this one came from a fellow holder who believes the management changes where in the works with the 4 million option award to AS a year and half ago at the 2014 AGM. Interesting.
Could contract news be timed to the arrival of a new leader?
Silence from Dr. Keith. Short interest has really dropped since July.
Waiting on status on AbbVie, Imperium and other highly watch programs. Just random rumblings.
RRM
UNS Price at posting:
17.0¢ Sentiment: Hold Disclosure: Held
